WRWilliam J. Ray

William J. Ray

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


William J. Ray has a total of 405 co-authors. Here are the top co-authors by number of shared publications:

  • George D. Hartman

    MRL, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States

    16 shared publications
  • Lei Ma

    MRL, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States

    15 shared publications
  • Marion Wittmann

    MRL, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States

    15 shared publications
  • Matthew A. Seager

    Departments of Medicinal Chemistry, Alzheimer's Research, and Drug Metabolism, Merck Research Laboratories , Sumneytown Pike, West Point, Pennsylvania 19486, United States

    12 shared publications
  • Charles D. Thompson

    MRL, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States

    11 shared publications
  • Kenneth A. Koeplinger

    MRL, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States

    11 shared publications

Latest Publications

  • Open Access

    Reduced LACTB expression in myeloid cells is associated with elevated succinylcarnitine and reduced Alzheimer’s disease risk

    by Alison Goate, Carmen Romero-Molina, Ruben Gomez-Gutierrez, Wen Yi See, Tulsi Patel, Hayk Davtyan, Jiacheng Ma, Quanyun Xu, Michael Sewell, Kendra Allton, et al.

    Lactamase β (LACTB) is a serine β-lactamase-like mitochondrial enzyme genetically associated with obesity, kidney disease, and hyperlipidemia. LACTB is located in an Alzheimer’s Disease (AD) risk locus and its expression in the brain has been genetically associated with AD susceptibility. The aim of this study was to investigate LACTB function and genetic link to AD in myeloid cells, due to their central role in modulating AD risk. Our Mendelian randomization analyses revealed that lower LACTB expression in myeloid cells is genetically associated with reduced disease susceptibility and increased succinylcarnitine, a metabolite independently associated with AD risk. We identified LACTB as a primary enzyme responsible for succinylcarnitine hydrolysis. In human macrophages and microglia, LACTB loss promoted enhanced oxidative phosphorylation, reduced protein synthesis and altered lipid homeostasis. LACTB expression was upregulated following interferon or TNF stimulation, and LACTB loss modified efferocytosis-related functions under inflammatory conditions. In vivo , xenotransplanted human LACTB knockout microglia showed enhanced association with amyloid plaques in the mouse brain. Together, these findings experimentally validated the genetic association between reduced LACTB expression and elevated succinylcarnitine and identified LACTB as an inflammation-responsive regulator of myeloid cell metabolism and function that may contribute to its protective genetic association with AD. Given its druggability and potential to use succinylcarnitine as a genetically-validated endophenotype and target engagement biomarker, LACTB represents a promising therapeutic target for AD.

  • Open Access

    Effect of choline supplementation in presymptomatic APOE ε4 carriers: a pilot study

    by William J. Ray, Yaima L. Lightfoot, Ronnie T. Trinh, Janelle Fawver‐Kahle, Susan Cooper, Li‐Huei Tsai, Jonathan Bortz, Isis Trujillo‐Gonzalez, Tianheng Zhang, Hulin Wu, et al.

    INTRODUCTION: With the advent of early detection biomarkers, it is possible to envision testing preventive strategies that delay the onset of Alzheimer's disease (AD). The ε4 allele of apolipoprotein E ( APOE ε4) is the strongest genetic risk factor for late‐onset AD; approximately 50% of all patients are APOE ε4‐positive. 1 APOE is the major central nervous system (CNS) lipoprotein, and studies have linked APOE4‐dependent deficits in lipid metabolism to disease‐relevant processes. 2–6 Choline, the precursor for phosphatidylcholine (PC), normalizes APOE ε4‐mediated lipid dysfunction in human model systems, 6 and low dietary choline intake correlates with increased disease risk or progression in mouse models and humans. 7–17 We therefore tested whether biomarkers and omics provided early evidence of choline CNS target engagement in an at‐risk population. METHODS: In a 6‐month open‐label phase 1 study (NCT05880849), asymptomatic APOE ε4 carriers ( n = 13; age 70 ± 5.5 years) received 2200 mg/day oral choline, with plasma and cerebrospinal fluid (CSF) collected before and after treatment. RESULTS: Choline was well tolerated with no serious adverse events. Treatment increased plasma and CSF choline and betaine, indicating systemic and CNS exposure. Exploratory lipidomics identified changes in plasma PC species and, in CSF, increases in ceramides and cholesterol esters. Although this study was not powered to assess biomarker efficacy, CSF neurofilament light (NfL) was lower at the end of treatment, and CSF phosphoserine‐181 tau (pTau181)/amyloid beta (Aβ)42 and plasma pTau217 showed directionally similar trends. DISCUSSION: These findings support randomized placebo‐controlled trials of choline in at‐risk populations and illustrate how fluid biomarkers and omics can de‐risk AD prevention studies.

  • Open Access

    Toward precision music medicine in oncology care: reproducible, scalable and biomarker-driven interventions

    by Annelise Huynh, Kyle Noll, William J. Ray, Frederick F. Lang, Mei Rui


  • Open Access

    DLK inhibition has sex-specific effects on neuroprotection and locomotor recovery after spinal cord injury

    by John C. Aldrich, Samantha M. Alman, Sydney E. Lee, Ashley R. Scheinfeld, Chelsea C. Zhang, Averi L. Pike, Fiona C. Bremner, Olivia Calderon, Sunil Goodwani, William J. Ray, et al.

    Spinal cord injury (SCI) causes devastating functional deficits, in part due to neuroinflammation, oxidative stress, and excitotoxicity that drive death of lesion-adjacent viable neurons. One signaling protein that promotes neuronal apoptosis and activates stress-responsive genes is dual leucine zipper kinase (DLK), which is a neuron-enriched kinase that responds to extracellular stress by activating the c-Jun N-terminal kinase (JNK) pathway. We hypothesized that SCI would robustly activate DLK signaling and that acute pharmacological inhibition of DLK would suppress JNK pathway activation, thereby enhancing neuroprotection and locomotor recovery in our mouse model of moderate contusion SCI. Using western blotting, we observed that SCI induced strong and sustained activation of the JNK pathway in the injured spinal cord starting at 4 hours post-injury through 7 days. Complementary analysis of single-nucleus RNA-seq revealed that DLK expression is highly enriched in neurons across all injury phases. Following SCI, neurons exhibited robust, time-dependent upregulation of multiple DLK-responsive transcripts, consistent with sustained pathway activation during the acute and subacute periods. Systemic treatment with the selective DLK inhibitor IACS’825 effectively suppressed intraspinal JUN activation in a dose-dependent manner. However, unexpectedly, DLK inhibition delayed functional recovery in male mice and expanded lesion volume by 71%, with no significant effect in females. These findings highlight the complex roles of DLK signaling after SCI, revealing a need to understand the sex-specific molecular mechanisms that modulate injury outcomes. Future studies should further optimize timing, location, and cellular targeting of DLK therapeutic strategies to improve neuroprotection and neurologic recovery after SCI.

  • Allosteric targeting of RIPK1: discovery of novel inhibitors via parallel virtual screening and structure-guided optimization

    by R. S. K. Vijayan, Matthew M. Hamilton, Dana E. Pfaffinger, Fernando G. Alvarez, Naphtali J. Reyna, Jennifer P. Bardenhagen, Hannah Shepard, Christian Rodriguez, Sunil Goodwani, Yaima Lightfoot, et al.

    Parallel virtual screening and structure-guided optimization enable discovery of novel allosteric RIPK1 inhibitors.


  • Open Access

    The pathogenicity of the glutamate metabolic cycle in schizophrenia determined by hippocampal spectroscopic profiling

    by Scott Small, Jia Guo, Ragy Girgis, Sunil Goodwani, Michael Soth, Christopher Wu, Stephen Rayport, William Ray, Douglas Rothman

    Hippocampal hyperactivity in schizophrenia is an early abnormality linked to its pathognomonic symptoms. An upregulation of the ‘glutamate metabolic cycle’, a pathway dedicated to maintaining normal synaptic excitability, is hypothesized to be pathogenic and to have therapeutic potential. Testing the hypothesis requires profiling the pathway’s three key metabolites -- glutamate, glutamine, and GABA. We begin by using a newly developed processing method capable of measuring these hippocampal metabolites via standard 1H-magnetic resonance spectroscopy (1H-MRS). We profiled the metabolites in patients with attenuated psychotic symptoms, a cohort enriched for early-stage schizophrenia and related psychotic disorders. More than just confirming abnormal pathway upregulation, the resultant profile isolated glutaminase 1 (GLS1) as the pathogenic driver. GLS1-dependent pathway upregulation was found to mechanistically underlie hippocampal hyperactivity and to associate with the illness’ symptoms. Next, to test the pathway’s therapeutic potential we used a newly developed 1H-MRS acquisition protocol optimized to measure the metabolites in mice. Hippocampal profiling GLS1 haploinsufficient mice showed that the pathway can be safely downregulated and identified a therapeutic goal. Profiling the effects of a GLS1 inhibiter that belongs to a drug family approved for clinical trials shows that the pathway can be pharmacologically targeted. Finally, profiling the effect of the inhibitor using the benchmark, ex-vivo mass spectrometry, validates that the new 1H-MRS tools are reliable biomarkers. Collectively, our findings can accelerate drug development for an illness that first strikes the hippocampus of young people before pathologically progressing and resulting in lifelong morbidity.


  • Open Access

    RIP Kinase 1 (RIPK1) modulates disease associated microglial response during demyelination

    by Sunil Goodwani, Yaima Luzardo Lightfoot, Bianca Gabrielle Ford, Olivia Calderon, Morgan McReynolds, Kendra Allton, Jiacheng Ma, Alexandra Botte, Ronnie The Pong Trinh, Troy Pearson, et al.

    Background: RIP Kinase 1 (RIPK1) is known to regulate necroptotic cell death in response to pro‐inflammatory signaling in cells where apoptotic signaling has been compromised. Aberrant RIPK1 activation has been implicated in several neurodegenerative disorders such as Alzheimer’s disease, Multiple Sclerosis, and Amyotrophic Lateral Sclerosis.Method: To investigate the role of RIPK1 in regulating the microglial response to demyelination, we administered a highly selective CNS penetrant RIPK1 inhibitor to C57Bl6 mice fed with cuprizone. We studied the microglial response using RNA Sequencing, single‐cell RNA Sequencing, lipidomics, and proteomics.Result: Transcriptomic analysis of isolated microglia and brain cytokine levels revealed that rapid demyelination induced by Cuprizone diet led to a strong disease‐associated microglia (DAM) response. Of the 1957 transcripts regulated in isolated microglia (padj<0.05) by the demyelination, RIPK1 inhibition significantly attenuated the microglial transcriptomic response of 497 transcripts (padj<0.1). Single‐cell RNA Sequencing analysis revealed that RIPK1 inhibition modified demyelination‐associated microglial sub‐clusters. Furthermore, soluble TREM2, a marker of microglia activation, was reduced, as were several cytokines in the brain. Open field analysis of these mice showed that RIPK1 inhibition rescued Cuprizone‐induced motor impairment. Proteomics and lipidomics analyses demonstrated RIPK1‐dependent changes in brain lipid metabolism.Conclusion: RIPK1 signaling promotes an inflammatory response that involves modulation of key regulatory pathways associated with demyelinating disorders.


  • Open Access

    A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation

    by William T. Ralvenius, Alison E. Mungenast, Hannah Woolf, Margaret M. Huston, Tyler Z. Gillingham, Stephen K. Godin, Jay Penney, Hugh P. Cam, Fan Gao, Celia G. Fernandez, et al.

    Pervasive neuroinflammation occurs in many neurodegenerative diseases, including Alzheimer’s disease (AD). SPI1/PU.1 is a transcription factor located at a genome-wide significant AD-risk locus and its reduced expression is associated with delayed onset of AD. We analyzed single-cell transcriptomic datasets from microglia of human AD patients and found an enrichment of PU.1-binding motifs in the differentially expressed genes. In hippocampal tissues from transgenic mice with neurodegeneration, we found vastly increased genomic PU.1 binding. We then screened for PU.1 inhibitors using a PU.1 reporter cell line and discovered A11, a molecule with anti-inflammatory efficacy and nanomolar potency. A11 regulated genes putatively by recruiting a repressive complex containing MECP2, HDAC1, SIN3A, and DNMT3A to PU.1 motifs, thus representing a novel mechanism and class of molecules. In mouse models of AD, A11 ameliorated neuroinflammation, loss of neuronal integrity, AD pathology, and improved cognitive performance. This study uncovers a novel class of anti-inflammatory molecules with therapeutic potential for neurodegenerative disorders.


  • Pathogenic tau–induced transposable element–derived dsRNA drives neuroinflammation

    by Elizabeth Ochoa, Paulino Ramirez, Elias Gonzalez, Jasmine De Mange, William J. Ray, Kevin F. Bieniek, Bess Frost

    Deposition of tau protein aggregates in the brain of affected individuals is a defining feature of “tauopathies,” including Alzheimer’s disease. Studies of human brain tissue and various model systems of tauopathy report that toxic forms of tau negatively affect nuclear and genomic architecture, identifying pathogenic tau–induced heterochromatin decondensation and consequent retrotransposon activation as a causal mediator of neurodegeneration. On the basis of their similarity to retroviruses, retrotransposons drive neuroinflammation via toxic intermediates, including double-stranded RNA (dsRNA). We find that dsRNA and dsRNA sensing machinery are elevated in astrocytes of postmortem brain tissue from patients with Alzheimer’s disease and progressive supranuclear palsy and in brains of tau transgenic mice. Using a Drosophila model of tauopathy, we identify specific tau-induced retrotransposons that form dsRNA and find that pathogenic tau and heterochromatin decondensation causally drive dsRNA-mediated neurodegeneration and neuroinflammation. Our study suggests that pathogenic tau–induced heterochromatin decondensation and retrotransposon activation cause elevation of inflammatory, transposable element–derived dsRNA in the adult brain.


  • Identification of CVN058, a Novel Brain Penetrant, Selective 5-HT3 Receptor Antagonist That Shows Efficacy in Pre-Clinical Cognition Models

    by Nicola Brice, Lee A. Dawson, David H. Margolin, Hans H. Schiffer, Holger Monenschein, William J. Ray, Stephen Hitchcock, Mark Carlton